BioPharma Resources

Drug Trial Radar · NCT05630807

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 1)

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 981 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

981

Actual

Start

Dec 7, 2022

Primary completion

Nov 11, 2025

Study completion Apr 15, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: a) Double-blind treatment (bepirovirsen or placebo) for 24 weeks. b) Nucleos(t)ide analogue (NA) treatment for 24 weeks. c) NA cessation stage OR Continue NA for 24 weeks. d) Durability of response and follow up for further 24 weeks for participants who stopped NA treatment at Week 48. The arms will be stratified based on HBsAg level (HBsAg greater than or equal to \[≥\] 100 international unit per milliliter \[IU/mL\] to less than or equal \[≤\]1000 IU/mL or greater than \[\>\] 1000 IU/mL to ≤3000 IU/mL) at screening. The total duration of the study, including screening (up to 60 days), the double-blind treatment stage (24 weeks), the On NA only stage (24 weeks), and the NA cessation and durability stages (48 weeks) is up to approximately 104 weeks at maximum for each participant.

Conditions

  • Chronic Hepatitis B
  • Hepatitis B, Chronic

Interventions

  • BepirovirsenDrug

    Bepirovirsen will be administered.

  • PlaceboOther

    Matching placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants achieving functional cure (FC) with baseline HBsAg ≤3000 IU/mLTime frame: Up to 72 weeks

Locations

177 sites in 26 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Davis, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Palo Alto, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Littleton, Colorado

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Richmond, Virginia

  • GSK Investigational Site

    Richmond, Virginia

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Capital Federal, Argentina

  • GSK Investigational Site

    Derqui Pilar, Argentina

  • GSK Investigational Site

    Rosario, Argentina

  • GSK Investigational Site

    Aracaju, Brazil

  • GSK Investigational Site

    Campinas, Brazil

  • GSK Investigational Site

    Curitiba, Brazil

  • GSK Investigational Site

    Manaus, Brazil

  • GSK Investigational Site

    Porto Alegre, Brazil

  • GSK Investigational Site

    Santa Maria, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Vila Mariana, Brazil

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Veliko Tarnovo, Bulgaria

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Victoria, British Columbia, Canada

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Saint-Jérôme, Quebec, Canada

  • GSK Investigational Site

    Beijing, China

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.